<![CDATA[Candidiasis has been increasingly prevalent worldwide, and the emergence of triazole resistance has become a marked challenge due to its link to higher mortality rates. Furthermore, there is significant variation in the resistance rate and species distribution among nations, underpinning the significance of local epidemiology to guide effective antifungal stewardship programs. The limited reports in Indonesia prompted us to do this study which main objectives were to characterize the species distribution of Candida spp. clinical isolates, determine the prevalence of triazole resistance among these isolates, and evaluate their clinical profile relevance at UGM Academic Hospital, Yogyakarta, Indonesia. Electronic health records, laboratory data, and clinical features of patients with specimens testing positive for Candida spp. were retrospectively collected between 2019 and 2021, and species distribution and clinical profiles of triazole resistance were analyzed descriptively and comparatively. A total of 185 clinical isolates were identified, with Candida tropicalis being the most dominant species (n=95; 51.4%), followed by Candida albicans (n=74; 40.0%) and Candida parapsilosis (n=4; 2.2%), indicating a shifted trend toward non-albicans Candida (NAC) species. The overall prevalence of triazole resistance among these isolates during the study period was 4.9% (n=9/185). No statistically significant differences in clinical characteristics were observed between the triazole-susceptible and the triazole-resistant groups. These findings highlight the emergence of NAC species in this setting and emphasize the need for continuous surveillance of antifungal resistance patterns among Candida spp. in Indonesia to inform local treatment guidelines and establish stewardship initiatives.]]>
